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Studies reporting an inverse relationship
between children’s blood lead levels (BLLs) of
10–24 µg/dL and cognitive function/perfor-
mance (Bellinger et al. 1991; Ruff et al. 1993)
motivated the Centers for Disease Control and
Prevention (CDC) to lower the level of con-
cern from a BLL ≥ 25 µg/dL to ≥ 10 µg/dL in
1991 (CDC 1991). Although prevention
efforts have resulted in an 86% decline in
BLLs ≥ 10 µg/dL in children in the United
States from the 1970s to the present, an esti-
mated 310,000 children < 6 years of age still
have BLLs ≥ 10 µg/dL (Schwemberger et al.
2005). A key prevention strategy has been to
identify children with BLLs ≥ 10 µg/dL and to
enroll them in case management to reduce
their lead burdens.
Collecting blood lead is considered to be
the most useful tool for screening and diag-
nostic testing (Agency for Toxic Substances
and Disease Registry 2005). Blood lead levels
correlate most closely with recent environ-
mental exposure. The excretory half-life of
lead in adult blood is approximately 36 days
(Todd et al. 1996), but estimates in children
are longer (Manton et al. 2000). Prolonged
exposure, which can come from both internal
and external sources, prevents BLLs from
declining to lower levels. The most common
external source of exposure in children is
deteriorated lead-based paint dust (CDC
1997). The most common internal exposure
source is from lead reservoirs in bone, which
are the largest component of body burden,
accounting for 70% of all lead in children,
and from where replenishment of lead in the
blood occurs. Half-life of lead in bone is usu-
ally measured in years or even decades
(Graziano 1994).
Although identification of the factors
inﬂuencing the time to reduce a child’s BLL
is essential to improving case management,
few studies have investigated this issue. New
York City investigators estimate that, on aver-
age, it takes 6–12 months for children’s BLLs
to decline from ≥ 20 µg/dL to < 10 µg/dL,
when medical and environmental manage-
ment is consistent with CDC recommenda-
tions for managing children with elevated
BLLs (Matte T, personal communication). 
An analysis of Wisconsin surveillance data
from 1995 to 1997 showed that BLLs
decreased 2.6 µg/dL per year, and the mean
time for decline among children with con-
firmed BLLs ≥ 20 µg/dL to drop below
10 µg/dL was just over 4 years (Wisconsin
Childhood Lead Poisoning Prevention
Program, unpublished data). A study pub-
lished in 2001 found that those with higher
peak BLLs take longer to decline to
< 10 µg/dL (Roberts et al. 2001). Speciﬁcally,
children with BLLs of 25–29 µg/dL required
on average 24 months to fall below 10 µg/dL
compared with children with BLLs of
10–14 µg/dL, who required 9.2 months.
However, those findings may have been
biased because the analysis did not take into
account the contribution of children whose
BLLs did not fall below 10 µg/dL. A more
recent study reported times of decline of 11.6
months in the 10–14 µg/dL category and
12.7 months in the 15–19 µg/dL category
among 2,109 children ≤ 3 years of age from
six states enrolled in case management; how-
ever, the authors also excluded children who
were censored in their analysis (Whitehead
and Leiker 2007).
To assess factors related to the time
required for children’s BLLs ≥ 10 µg/dL to
decline, we analyzed routinely collected blood
lead surveillance data from lead poisoning
prevention programs in Vermont and North
Carolina. We compared three different ana-
lytic approaches: a) a central analysis that
included censoring children whose BLLs did
not fall below 10 µg/dL at the time of their
last test; b) an analysis that simply excluded
children who were censored; and c) a sensitiv-
ity analysis that inferred the time for chil-
dren’s BLLs to fall below 10 µg/dL on the
basis of linear interpolations between the
times of the last measurement above and the
ﬁrst measurement below the level of concern.
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BACKGROUND: Few studies have examined factors related to the time required for children’s blood
lead levels (BLLs) ≥ 10 µg/dL to decline to < 10 µg/dL. 
OBJECTIVES: We used routinely collected surveillance data to determine the length of time and risk
factors associated with reducing elevated BLLs in children below the level of concern of 10 µg/dL. 
METHODS: From the North Carolina and Vermont state surveillance databases, we identified a
retrospective cohort of 996 children < 6 years of age whose ﬁrst two blood lead tests produced levels
≥ 10 µg/dL during 1996–1999. Data were stratiﬁed into ﬁve categories of qualifying BLLs and ana-
lyzed using Cox regression. Survival curves were used to describe the time until BLLs declined
below the level of concern. We compared three different analytic methods to account for children
lost to follow-up. 
RESULTS: On average, it required slightly more than 1 year (382 days) for a child’s BLL to decline
to < 10 µg/dL, with the highest BLLs taking even longer. The BLLs of black children [hazard ratio
(HR) = 0.84; 95% confidence interval (CI), 0.71–0.99], males (HRmale = 0.83; 95% CI,
0.71–0.98), and children from rural areas (HRrural = 0.83; 95% CI, 0.70–0.97) took longer to fall
below 10 µg/dL than those of other children, after controlling for qualifying BLL and other covari-
ates. Sensitivity analysis demonstrated that including censored children estimated a longer time for
BLL reduction than when using linear interpolation or when excluding censored children. 
CONCLUSION: Children with high confirmatory BLLs, black children, males, and children from
rural areas may need additional attention during case management to expedite their BLL reduction
time to < 10 µg/dL. Analytic methods that do not account for loss to follow-up may underestimate
the time it takes for BLLs to fall below the recommended target level.
KEY WORDS: blood lead level, capillary, chelation, children, surveillance, venous. Environ Health
Perspect 116:981–985 (2008). doi:10.1289/ehp.10548 available via http://dx.doi.org/ [Online
5 March 2008]Methods
Study design and population. The Childhood
Lead Poisoning Prevention Branch of the
CDC maintains the Childhood Blood Lead
Surveillance database, consisting of childhood
blood lead surveillance data from 43 states.
States considered for inclusion in this study
were those that submitted 1996–1999 surveil-
lance data to the CDC. During this period,
two of these states (Vermont and North
Carolina) submitted data that included at least
two tests on the majority (> 90%) of children
with BLLs ≥ 10 µg/dL (n = 1,368 children).
We excluded 292 children who were > 6 years
of age during their ﬁrst elevated screening test,
74 children who had only two total tests, and 6
children whose records indicated that they had
received chelation therapy to lower their BLL.
We limited our analysis to children < 6 years of
age with at least three tests: a) an initial ele-
vated capillary, venous, or unknown sample
screening test; b) an elevated confirmatory
venous test (qualifying BLL); and c) a follow-
up test (n = 996). Time to decline began at the
qualifying blood lead test. The restriction to
use venous samples at the confirmatory test
avoids a potential positive bias associated with
BLLs resulting from capillary tests (Anderson
et al. 2007; Schlenker et al. 1997).
Data analysis. Kaplan–Meier survival
curves were constructed to assess factors associ-
ated with shorter time for BLLs to fall below
10 µg/dL. The independent variables of inter-
est were age at qualifying BLL, sex, race, state
of residence, and urban/rural status. All factors
were coded using indicator variables, except
age at qualifying BLL, which was treated as
continuous. The qualifying BLL result was cat-
egorized into quintiles, so we could compare
our results with those of Roberts et al. (2001).
We considered children to be from an urban
area if they lived in a metropolitan statistical
area in Vermont or North Carolina (U.S.
Census Bureau 2002); we classified children
not living in an urban area as rural. Vermont
had three counties and North Carolina had
41 counties categorized as urban. Children
who were not classified as white, black,
Hispanic, or “missing race” had their race cate-
gorized as “other.” We included children not
documented to have attained a BLL < 10
µg/dL in the analysis, and censored at the time
of their last test. Follow-up stopped at the time
of a child’s last test (Kalbﬂeisch and Prentice
1980). We called this the central analysis.
We used log/log survival curves and
extended Cox models to evaluate whether each
variable met the proportional hazards assump-
tion. All variables met this assumption except
for qualifying BLL. Therefore, we stratiﬁed the
analysis by qualifying BLL category in sum-
mary models and also analyzed associations
separately within categories deﬁned by qualify-
ing BLL category. We screened for collinearity
by examining correlations between indepen-
dent variables. No correlation coefficients
exceeded 0.5, even within strata of the qualify-
ing BLL categories (results not shown).
Backward selection regression was used to
identify the most predictive models, with a
critical p-value of 0.05 used to determine entry
into the model. We used likelihood ratio tests
Dignam et al.
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Table 1. Characteristics of the cohort tested for
blood lead in Vermont and North Carolina,
1996–1999 (n = 996).
Characteristic No. (%)
Qualifying blood lead level range (µg/dL)
10–14 452 (45.4)
15–19 315 (31.6)
20–24 112 (11.3)
25–29 59 (5.9)
≥ 30 58 (5.8)
Total 996 (100.0)
Sex
Male 540 (54.2)
Female 452 (45.4)
Unknown 4 (0.4)
Total 996 (100.0)
Race
White 397 (39.9)
Black 399 (40.1)
Native American/Alaskan Native 10 (1.0)
Asian/Paciﬁc Islander 10 (1.0)
Hispanic 94 (9.4)
Other 3 (0.3)
Unknown 83 (8.3)
Total 996 (100.0)
State of residence
Vermont 230 (23.1)
North Carolina 766 (76.9)
Total 996 (100.0)
Sample type at initial blood lead level
Venous 526 (52.8)
Capillary 432 (43.4)
Unknown 38 (3.8)
Total 996 (100.0)
Location of residence
Rural 546 (54.8)
Urban 450 (45.2)
Total 996 (100.0)
Age range at qualifying blood lead level (months)
< 12 52 (5.2)
12–23 491  (49.3)
24–35 199 (20.0)
36–47 110 (11.0)
48–59 81 (8.1)
60–72 63 (6.4)
Total 996 (100.0)
Figure 1. Kaplan–Meier curves of the time required for blood lead levels to drop below 10 µg/dL among
children < 6 years of age tested for blood lead from Vermont and North Carolina in 1996–1999, stratiﬁed by
qualifying (Qual) BLL (µg/dL) (n = 996).
1.00
0.75
0.50
0.25
0.00
S
u
r
v
i
v
a
l
 
d
i
s
t
r
i
b
u
t
i
o
n
 
f
u
n
c
t
i
o
n
0 200 400 600 800 1,000 1,200 1,400
No. of days until BLLs drop below 10 mg/dL
Qual_BLL = 10–14
Qual_BLL = 15–19
Qual_BLL = 20–24
Qual_BLL = 25–29
Qual_BLL = ≥ 30
Table 3. Best predictors of the time required for BLLs to drop below 10 µg/dL overall and by qualifying BLL
range, among a cohort of children tested for blood lead from Vermont and North Carolina, 1996–1999.
Variable β SE p-Value HR 95% CI
Overalla (n = 996)
Black –0.1782 0.0858 0.0378 0.84 0.71–0.99
Male –0.1859 0.0828 0.0248 0.83 0.71–0.98
Rural addressb —— ———
Qualifying BLL: 10–14 µg/dLc (n = 452)
Rural address –0.1359 0.1101 0.2171 0.87 0.70–1.08
Qualifying BLL: 15–19 µg/dLc (n = 315)
Rural address –0.2048 0.1575 0.1935 0.82 0.60–1.11
Qualifying BLL: 20–24 µg/dLc (n = 112)
Rural address –0.7332 0.2883 0.0110 0.48 0.27–0.85
Qualifying BLL: 25–29 µg/dLc (n = 59)
Rural address 0.9427 0.5213 0.0705 2.57 0.92–7.13
Qualifying BLL: ≥ 30 µg/dLc (n = 58)
Rural address –0.8428 0.6509 0.1954 0.43 0.12–1.54
aAdjusted by qualifying BLL using stratiﬁcation. bAssociation with child’s address differs signiﬁcantly by qualifying BLL
(p = 0.04) and is not reported overall. cSeparate analysis within qualifying BLL stratum. to assess potential interactions. Significance
was determined at the 0.05 level. There was
evidence of statistical interaction between the
child’s area of residence and qualifying BLL in
relation to the time required for children’s
BLLs to decline to < 10 µg/dL (p = 0.0374).
We also evaluated the effects that different
methods of analyses could have on resulting
time to BLLs declining to < 10 µg/dL. We
accomplished this by conducting two addi-
tional analyses: a) to make a comparison with
the Roberts et al. (2001) study, we conducted
an analysis in which the censored children were
excluded; and b) we performed an analysis in
which the amount of time for a BLL to reach
below 10 µg/dL from the time between the last
BLL > 10 µg/dL and the ﬁrst BLL < 10 µg/dL.
All analyses were done using SAS version 9.1
(SAS Institute Inc., Cary, NC).
Results
Among the 996 children in the study, the
mean (± SD) initial BLL was 19.6 ± 8.2
µg/dL. The average number of days between
the initial and qualifying blood lead tests was
49.6 days. About 77% of the children were
from North Carolina, 40% were white, 40%
were black, and more than two-thirds of the
children were 12–35 months of age—the
time when children are at most risk for ele-
vated BLLs (Table 1). The mean age of the
children at qualifying BLL was 2.1 ± 1.3
years. Children who were excluded from the
study cohort were similar in demographics
and initial BLL (data not shown). Males
tended to have a higher mean initial BLL
compared with females (19.9 µg/dL and
18.8 µg/dL, respectively), but this difference
was not significant (p = 0.305). Overall, the
median time to attain a BLL < 10 µg/dL was
382 days [95% confidence interval (CI),
356–418 days], slightly more than 1 year
(range, 22–1,285 days). In the cohort, cen-
sored children (n = 408) contributed 5 to
1,086 days and uncensored children (n =
588) were followed from 22 to 1,280 days.
Children who were censored had similar
demographics, and on average, had slightly
higher initial BLLs than did children whose
BLLs dropped below 10 µg/dL.
We found clear differences in the time
required for BLLs to drop below 10 µg/dL
based on the child’s qualifying BLL category
(Figure 1). As expected, children with higher
qualifying BLLs took the longest to reach a
BLL < 10 µg/dL when compared with the
lower BLL categories. A log-rank test for
trend was statistically signiﬁcant (χ2 = –12.2,
df = 4, p < 0.0001), reinforcing the visual
impression of the trend toward longer times
of decline among children with higher BLL
categories. Children in the BLL category
25–29 µg/dL took > 2.5 years to decline to
< 10 µg/dL (median no. of days = 954; 95%
CI, 750–1,057) and children in BLL category
≥ 30 µg/dL took 3 years to reach a BLL
< 10 µg/dL (median no. of days = 1,083;
95% CI, 917–1,083) (Table 2).
Race, sex, and area of residence were also
predictors of the time required for a child’s
BLL to drop below 10 µg/dL (Table 3). The
median time for BLLs to decline to < 10 µg/dL
was approximately 363 days for white children
compared with 420 days for black children.
Male children had a median time of decline of
400 days compared with 363 days among
female children. Children living in rural areas
had a median time of decline of 400 days,
whereas children living in urban areas required
360 days.
The median time required for black chil-
dren’s BLLs to decline to < 10 µg/dL took
longer than those of all children in the central
analysis in each BLL category except in the
20–24 µg/dL BLL category (where it was the
same) (Table 2). BLLs of black children con-
sistently required > 33 months to fully decline,
regardless of the qualifying BLL category.
When stratified by qualifying BLL cate-
gory, the analysis in which we excluded cen-
sored children yielded the shortest median
times for a child’s BLL to decline below
10 µg/dL. The linear interpolation sensitivity
analysis yielded median times of decline that
were consistently lower in each qualifying BLL
category when compared with the central
analysis and consistently higher when com-
pared with the analysis that excluded censored
children (except in the 10- to 14-µg/dL BLL
category) (Table 2).
Discussion
The BLLs of black children took longer to
decline than those of others, regardless of
qualifying BLL range. This ﬁnding was signif-
icant after adjusting for qualifying BLL cate-
gory and other independent variables. It is
not clear from these surveillance data why this
racial disparity exists. One possible explana-
tion is that black children are not receiving
timely and appropriate follow-up care.
Findings from Kemper et al. (2005) provide
evidence of differences in follow-up. These
researchers found that among Medicaid-
enrolled children < 6 years of age with ele-
vated screening tests, follow-up was lower for
Hispanic or black children than for white
children. A key intervention to reduce chil-
dren’s BLLs is to identify and remove all
sources of lead exposure (CDC 2002). The
slower decline in BLLs among black children
may reﬂect a greater length of time to identify
and/or remove lead sources. 
Another possible explanation for the
longer time for black children’s BLLs to
decline is that the children may have been
exposed to lead for a longer period of time
than other children. Previous studies have
documented a higher prevalence of BLLs
≥ 10 µg/dL among children who are black
(Dignam et al. 2004; Lanphear et al. 1996;
Meyer et al. 2003; Pirkle et al. 1998;
Raymond et al. 2007; Schwemberger et al.
2005). When ongoing exposures of lead
decline, BLLs decline, but lead is also stored
in bone (Hu and Hernandez-Avila 2002).
Past maternal lead exposures that are stored in
bone can be mobilized during pregnancy and
lactation and expose the developing fetus. If
children are exposed both prenatally and
postnatally, this accumulated exposure may
take longer to reduce BLLs.
The BLLs of male children took longer to
decline than those of female children, after
adjustment. It has been established that adult
males have higher BLLs than adult females
(Counter et al. 2001; Pirkle et al. 1998). This
is thought to be attributable to generally higher
exposures among men, because men have
higher blood hematocrit levels, as lead in blood
binds to red blood cells (Vahter et al. 2007),
Reduction of elevated blood lead levels in children
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Table 2. Unadjusted median time [days (95% CI)] of the time required for BLLs to drop below 10 µg/dL by analysis type and selected covariates, among a cohort of
children tested for blood lead in Vermont and North Carolina, 1996–1999.
Qualifying blood lead level (µg/dL)
Type of analysis 10–14 15–19 20–24 25–29 ≥ 30
Central (n = 996) 237 (211–284) 424 (362–479) 659 (593–774) 954 (750–1,057) 1,083 (917–1,083)
Excluding censored children (n = 588) 191 (175–216) 267 (224–301) 463 (352–598) 750 (479–954) 723 (151–917)
Interpolated time to end point (n = 996) 125 (103–151) 340 (292–401) 564 (483–684) 762 (606–992) NA
Central, black children (n = 399) 265 (211–306) 479 (378–636) 659 (593–863) 957 (750–1,057) NA
Central, white children (n = 397) 230 (194–306) 377 (305–502) 686 (363–823) 1,075 (460–1,075) 1,083 (932–1,083)
Central, male children (n = 540) 258 (201–306) 427 (377–566) 598 (559–788) 825 (750–1,057) NA
Central, female children (n = 452) 232 (195–288) 370 (294–476) 686 (509–798) 1,056 (525–1,198) 917 (754–932)
Central, rural address (n = 546) 269 (220–316) 440 (355–602) 774 (659–823) 818 (525–957) 1,083 (854–1,083)
Central, urban address (n = 450) 214 (182–266) 386 (294–479) 509 (332–598) 1,056 (750–1,198) NA
NA, not availableand attributable to the increased skeletal mass
of men compared with women (White and
Sabbioni 1998). However, in young children
differences in mean BLLs between young boys
and girls have not been found (Baghurst et al.
1992; Strömberg et al. 2003).
Children from rural counties took longer
for their BLLs to decline than children living
in urban counties. It is not clear from these
surveillance data why this geographic differ-
ence exists. Children from rural areas may not
always receive timely medical follow-up, home
visits, and lead source investigations, possibly
because of transportation and other health
care access issues. We examined the number of
days between the qualifying and follow-up
blood lead tests by urban/rural status as a
measure of follow-up timeliness. Rural chil-
dren required a slightly longer time (148.8
days) for follow-up than did urban children
(140.9 days), but the difference was not signif-
icant (p = 0.345). Additionally, children from
rural counties tend to live in parts of North
Carolina and Vermont with a larger number
of older housing as a percentage of all housing,
giving families who have children with ele-
vated BLLs fewer choices to relocate to lead-
safe housing. For both states combined, the
percent of pre-1950 housing in rural areas is
21.6% compared with 13.6% in urban areas.
As expected, we found that the length of
time for children’s BLLs to drop below
10 µg/dL depended on the qualifying BLL.
Roberts et al. (2001) demonstrated that the
time of clearance of toxics from the body
without pharmacologic intervention is
directly proportional to the peak concentra-
tions of those toxics in the blood. We used
the qualifying BLL in our study to categorize
the baseline value because these levels were
predominantly the peak concentrations
observed and were all venous sample types.
The efficacy of chelation therapy to reduce
the adverse health effects of elevated BLLs has
not been demonstrated for BLLs < 45 µg/dL
(Liu et al. 2002; Rogan et al. 2001). Although
we excluded from our analysis records that
indicated that chelation was administered, it
is possible that some of the remaining 1.0%
of children with BLLs ≥ 45 had been
chelated. This may have slightly decreased the
overall amount of time observed in this study
for children’s BLLs to drop below 10 µg/dL
among children with a high qualifying BLL.
The comparison of three different analytic
approaches allowed us to assess the impact that
censoring had on the estimate of the time to
attain the desired BLL. Typically in survival
analyses, individuals who do not reach an event
(in this case, a BLL < 10 µg/dL) are censored at
the end of their follow-up period. Therefore, in
our central analysis, the contribution of time
from children whose BLLs remained elevated
was censored when their last test was recorded.
We hypothesized that excluding children whose
BLLs failed to return to < 10 µg/dL would lead
to an underestimation of the time until BLLs
dropped below 10 µg/dL. Even though it was
inappropriate to exclude censored children in
the analysis, we wanted to compare our results
with those of Roberts et al. (2001). When cen-
sored children were excluded, we found dra-
matically shorter times of decline, validating
this expectation. 
We also observed shorter times of decline
compared with the Roberts et al. (2001) study
in each BLL stratum except at the 25–29
µg/dL level (and the ≥ 30 µg/dL level, because
their study did not have the category), regard-
less of how we analytically treated children
whose BLL did not drop below 10 µg/dL. It is
unclear why the study by Roberts et al.
(2001), which excluded censored children,
reported longer median times of decline. One
reason may be the racial composition of the
study populations. The Roberts et al. (2001)
study comprised 98% African-American chil-
dren, whereas our study population was
equally white and black. A more recent study
by Whitehead and Leiker (2007) also reported
longer times of decline in the 10–14 and
15–19 µg/dL categories (348 and 381 days,
respectively) among children ≤ 3 years of age
who were enrolled in case management.
However, the authors used analysis of variance
and excluded children who did not attain a
BLL < 10 µg/dL in their analysis.
In our central analysis we did not know
precisely when BLLs declined to < 10 µg/dL,
so in additional analyses, we used linear inter-
polation (sensitivity analysis) to estimate time
to this event. These results are more likely to
approximate the true time until the desired
end point than the central analysis because lin-
ear interpolation estimates the time at which
children’s BLLs initially decline to < 10 µg/dL.
The large number of children censored
before their BLLs fell below 10 µg/dL
(40.9%) suggests that many children may be
lost to follow-up. Children with elevated
BLLs are frequently from lower socio-
economic backgrounds, and follow-up testing
may not always occur because of transporta-
tion and other health care access issues. In
addition, some health care providers and lead
poisoning prevention programs may stop pro-
viding follow-up services when BLLs fall
below 15 µg/dL. In our study we compen-
sated for missing blood lead test results
< 10 µg/dL by censoring. A bias could have
resulted if the time to decline of BLLs to
< 10 µg/dL of those censored differed from
that of those children whose BLLs declined to
< 10 µg/dL. Similarly, because time until doc-
umentation of BLLs to decline to < 10 µg/dL
was measured in the central analysis, those
results are probably conservative estimates of
the true time in this cohort of children.
Another limitation of this study was
incomplete data resulting in an inability to
control for other important demographic/risk
factors that might inﬂuence time until BLLs
decline to < 10 µg/dL. For example, informa-
tion on the age of houses, to assess risk for
lead paint exposure, was known for only a few
children, so its impact could not be fully
assessed. Similarly, information was infre-
quently recorded for Medicaid status (a risk
factor for elevated BLLs) and, in a small num-
ber of cases, whether chelation therapy was
administered. We would have liked to con-
sider these issues in our analysis. We also
would have liked to assess whether children
with several address changes during the
period of analysis were more likely to have
longer times until decline or learn of the
results of environmental investigations, but
detailed address and environmental investiga-
tion data were not available. Finally, we did
not estimate the biologic half life of lead. We
refrained from this approach because we felt
that the decline in BLLs reflected not only
biologic clearance, but also potentially ongo-
ing or recurring exposures, case management,
and other behavioral factors. These are areas
that need further investigation.
In conclusion, having a high conﬁrmatory
BLL, being black, being male, and living at a
rural address are associated with a longer time
until BLLs decline to < 10 µg/dL. Further
study is needed to understand these and other
factors associated with longer times until
decline of BLLs to < 10 µg/dL. The CDC rec-
ommends more efforts to remove lead-based
paint hazards in and around housing before
children have elevated BLLs (CDC 2002).
Targeted efforts to prevent further lead expo-
sure and aggressive case management for chil-
dren with elevated BLLs may help reduce lead
burden in children. Childhood lead poisoning
programs must also move away from relying
solely on screening and case management
activities and focus on preventing lead expo-
sure through the implementation of housing-
based primary prevention.
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